ANI Pharma Inc Exchange Agreements
17 Contracts & Agreements
- Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under theSecurities... (Filed With SEC on May 4, 2017)
- Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under theSecurities... (Filed With SEC on May 4, 2017)
- Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under theSecurities... (Filed With SEC on May 5, 2016)
- Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under theSecurities... (Filed With SEC on May 5, 2016)
- Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for ConfidentialTreatment under Rule 406 under the Securities... (Filed With SEC on November 3, 2015)
- Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under theSecurities... (Filed With SEC on November 3, 2015)
- Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities... (Filed With SEC on November 10, 2014)
- Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the... (Filed With SEC on December 11, 2012)
- Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the... (Filed With SEC on December 11, 2012)
- Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the... (Filed With SEC on December 11, 2012)
- Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the... (Filed With SEC on December 11, 2012)
- Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the... (Filed With SEC on December 11, 2012)
- Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the... (Filed With SEC on December 11, 2012)
- Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the... (Filed With SEC on December 11, 2012)
- BIOSANTE PHARMACEUTICALS, INC. SECURITIES EXCHANGE AGREEMENT FEBRUARY 15, 2012 (Filed With SEC on May 8, 2012)
- BIOSANTE PHARMACEUTICALS, INC. SECURITIES EXCHANGE AGREEMENT FEBRUARY 7, 2012 (Filed With SEC on May 8, 2012)
- LICENSE AGREEMENT between PERMATEC TECHNOLOGIE, AG and BIOSANTE PHARMACEUTICALS, INC. [Portions of this Exhibit have been omitted pursuant to a request for confidentiality under... (Filed With SEC on March 16, 2011)
